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Background: Diabetes mellitus counts as a major risk factor for developing atherosclerosis. The activation of
protein kinase C (PKC) is commonly known to take a pivotal part in the pathogenesis of atherosclerosis, though
the influence of specific PKC isozymes remains unclear. There is evidence from large clinical trials suggesting
excessive neurohumoral stimulation, amongst other pathways leading to PKC activation, as a central mechanism in
the pathogenesis of diabetic heart disease. The present study was therefore designed to determine the role of
Gq-protein signalling via Ga11 in diabetes for the expression of PKC isozymes in the coronary vessels.
Methods: The role of Ga11 in diabetes was examined in knockout mice with global deletion of Ga11 compared to
wildtype controls. An experimental type 1-diabetes was induced in both groups by injection of streptozotocin.
Expression and localization of the PKC isozymes a, bII, δ, ε, and ζ was examined by quantitative
immunohistochemistry.
Results: 8 weeks after induction of diabetes a diminished expression of PKC ε was observed in wildtype animals.
This alteration was not seen in Ga11 knockout animals, however, these mice showed a diminished expression of
PKCζ. Direct comparison of wildtype and knockout control animals revealed a diminished expression of PKC δ and
ε in Ga11 knockout animals.
Conclusion: The present study shows that expression of the nPKCs δ and ε in coronary vessels is under control of
the g-protein Ga11. The reduced expression of PKC ζ that we observed in coronary arteries from Ga11-knockout
mice compared to wildtype controls upon induction of diabetes could reduce apoptosis and promote plaque
stability. These findings suggest a mechanism that may in part underlie the therapeutic benefit of RAS inhibition
on cardiovascular endpoints in diabetic patients.
Background
Diabetes mellitus is a major risk factor for developing
coronary artery disease. In the diabetic population ather-
osclerosis accounts for 80% of all deaths compared to
one third in the general population. Numerous studies
have addressed the complex pathogenesis of coronary
artery disease. It is assumed that distinct stages can be
defined in the progression of the disease. These contain
the monocyte and endothelium mediated oxidation of
LDL (oxLDL), the monocyte recruitment and extravasa-
tion, the formation of foam cells most likely mediated
through scavenger receptors followed by inflammatory
responses that lead to the building of atherosclerotic
plaques, which potentially rupture and lead to myocar-
dial infarction/ischemia.
In a diabetic environment certain mechanisms exist
which are incriminated to promote the formation of
atherosclerotic lesions. The building of advanced glyca-
tion end products (AGEs) which is mainly determined
by the level of glucose and time of exposure, the induc-
tion of hyperglycaemia induced oxidative stress, hyper-
glycaemia mediated inflammation through cytokines
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activation of the hexosamine pathway and the regulation
of proteinkinase C (PKC) activity are interacting and
engaging in the pathogenesis of atherosclerosis as
described above. Numerous operations of these demon-
strate a participation of PKC activation. First of all PKC
activation increases the pro-oxidant environment by
increasing the production of reactive oxygen species in
the endothelium [1] supporting the formation of oxLDL.
Next the endocytosis of oxLDL can be mediated by
scavenger receptors that are controlled by PKC [2]. This
oxLDL leads to the release of granulocyte-macrophage-
colony-stimulating-factors (GM-CSF) which can be
blocked by general PKC blockage [3]. Other factors
beside the GM-CSF-release contribute for the monocyte
adhesion like the expression of P-selectin that is upregu-
lated by PKC activation [4]. Adhesion of monocytes and
accumulation of oxLDL results in the formation of cho-
lesterol loaded foam cells and characteristic athero-
sclerotic lesions. Typical for the development of more
complex lesions is the proliferation and migration of
vascular smooth muscle cells (VSMCs) in the suben-
dothelial space which is influenced by different isozymes
of PKC [5]. Furthermore the expression of different
metallomatrix-proteinases (MMPs), which play a crucial
role for the plaque stability and the process of plaque
rupture [6], are affected by PKC. So the central role of
PKC in all steps of the formation of atherosclerotic pla-
ques is reflected broadly. In addition, functional exami-
nations show a differential pattern of endothelial barrier
properties and therefore the permeability of the
endothelium depending on the activation of PKC [7].
PKC is a family of at least twelve isozymes and the
particular involvement of the different isozymes is only
poorly understood. The family of PKC isozymes is
divided in subgroups in order of their enzymatic quali-
ties: The conventional PKCs (cPKC) consist of the iso-
zymes a, b and g, which are activated in the function of
calcium and diacylglycerol (DAG). The new PKCs
(nPKC) include the isozymesε, h, δ,a n d θ, which are
activated independently of calcium but in dependence of
DAG. The atypical PKCs (aPKC) τ and ζ are activated
independently of calcium and DAG. However, the role
of PKCs in several important biological processes
remains to be elucidated.
In a hyperglycaemic state not only hyperglycaemia per
se, but also excessive neurohumoral stimulation are held
responsible for the activation of the PKC isozymes [8,9].
In cardiac tissue, many of these neurohumoral peptides
like angiotensin II, endothelin-1 or noradrenalin, which
promote vasoconstriction and oxidative stress, bind to
receptors that are coupled to the Gq-protein Ga11.
Interestingly the blockage of the renin-angiotensin-sys-
tem (RAS) revealed a significant benefit in controlled
randomised studies in a diabetic population [10,11].
These clinical observations are supported by animal
models in which the blockage of the RAS showed a
significantly diminished progression of atherosclerosis
[12,13].
Based on these results we generated the hypothesis
that a signalling pathway involving the Gq-protein Ga11
may substantially mediate the pattern of PKC isoform
expression in diabetes and therefore potentially
atherogenesis.
To gain further insight in the complex pathological
pathways, the present study analyzed the role of Ga11
on levels of expression of specific PKC isozymes distri-
bution in the coronary vessels in an early diabetic
environment.
Methods
Induction and verification of experimental induced
STZ-diabetes
Investigations were carried out with Ga11 knockout
mice and wildtype mice of the same line (C57/Bl6).
Generation of the knockout mice was described pre-
viously [14]. C57BL6 wild type mice were obtained from
Charles River Laboratories (Sulzfeld, Germany). The
experimental design was approved by proper authorities
and controlled by the Animal Welfare Officer of the
University of Cologne (certificate AZ 50.203.2-K47,28/
04). Mice 8 weeks of age were injected intraperitoneally
with a single dose of either STZ in 0.1 mol/l citrate buf-
fer, pH 4.5 (130 mg/kg), or citrate buffer. 24 hours later,
blood glucose levels were determined using a Gluc-
ometer (GlucoMen Glycó) and Glucostix (GlucoMen
S e n s o r ,A .M e n a r i n iD i a g n o s t i cs) to establish induction
of diabetes. Afterwards the blood glucose levels and
body weight of mice were monitored weekly. Successful
induction of diabetes was defined by a constant blood
glucose >300 mg/dl over 8 weeks. Throughout the
study, animals were housed at 20-22°C with fixed 12 h
day/night cycle and given free access to food and water.
Sample Collection and Tissue Preparation
After 8 weeks of the diabetic status, animals were killed
by cervical dislocation. Thoracic cavities were opened
and hearts were removed and immersion-fixed using a
fixative containing 4% paraformaldehyde and 0.2% picric
acid in 0.1 M phosphate buffer salt (PBS), pH 7.4 for 24
ha t4 ° C .A f t e rw a s h i n gi n0 , 1MP B S ,p H7 , 4 ,2 4h ,a t
4°C, specimen were cryoprotected with 20% saccharose
in 0,1 M PBS, pH 7,4, 48 h, at 4°C. Specimen were
embedded in tissue-tek and quick-frozen in fluid nitrate.
Specimens were cryosectioned with a thickness of 7 μm
in consecutive sections. The hearts from 6 normal glyce-
mic mice and 6 diabetic mice were presently analyzed in
each group.
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The rabbit anti-proteinkinase C δ-monoclonal antibody,
the rabbit anti-protein kinase C bII-monoclonal anti-
body and the rabbit anti-protein kinase C ε-monoclonal
antibody was purchased from Sigma Immunochemicals,
St. Louis, MO, USA. The rabbit anti-protein kinase C
ζ-monoclonal antibody and the rabbit anti-protein
kinase C a-monoclonal antibody and were purchased
from Cell Signaling Technology, Inc., Boston, MA, USA.
All other reagents were of analytical grade or the best
grade commercially available.
Immunohistochemistry
In consecutive sections, Avidin-Biotin-Peroxidase Com-
plex Method was performed for the immunohistochemical
incubations (Elite ABC Kit, Vector Labor, Peterborough,
UK). Endogenous peroxidases were inhibited with 0.3%
H2O2. To block non-specific bindings, we treated sections
with 1% bovine serum albumin (BSA) + 10% normal goat
serum (NGS). Thereafter, sections were incubated for 24
hrs at 4°C with primary monoclonal antibodies against
PKC isoforms followed by incubation with biotin-conju-
gated goat anti-rabbit IgG (1:500) and biotinylated anti-
mouse IgG (1:500), respectively. The sections were then
treated with avidin-biotinperoxidase complex (1:100) for
1 hr. The reaction was visualized with 0.05% 3,39-diami-
nobenzidine tetrahydrochloride (Sigma) in 0.05 M Tris-
HCl buffer, pH 7.6, containing 0.01% H2O2 and 0.01%
nickel ammonium sulphate. Incubations without the pri-
mary or secondary antisera and pre-absorption were car-
ried out as negative controls.
Quantification of Immunohistochemistry
The densitometric staining intensities of the PKC iso-
forms in treated and in control sections were measured
by image analysis of grey values of immunostaining. The
background grey value was measured from four selected
regions at a cell free area. The blood vessels grey values
were measured from four selected areas of the across
sectioned blood vessels wall. Immunostaining intensity
was presented as the mean of measured blood vessels
grey value minus mean of measured background grey
value. For staining intensity detection a Zeiss Axiophot
microscope coupled to a 3-chip CCD-camera was used
and the analysis was performed using the Optimas 6.00
image analysis program (Imaging Technology Inc., San
Diego, CA, USA).
Statistical analysis
Differences among groups were compared with student’s
t-test for unpaired observations. The data shown are
means ± SE. The level of significance was set to P <0.05.
All P values reported were based on two-sided tests.
Results
Induction of STZ-induced experimental diabetes
At the beginning of the study the animals showed no
significant difference in the blood glucose levels. For
those animals injected with citrate buffer the blood glu-
cose level remained the same for the observed period of
8 weeks. Animals injected with STZ 130 mg/kg showed
a significant increase to 491 ± 91 mg/dl in the wildtype
group (P < 0,001) and to 432 ± 107 mg/dl in the Ga11
knockout group (P < 0,001) at the end of the in vivo
study (Table 1). Another typical sign of type 1 diabetes
beside the catabolic state was an observed polyuria and
ketonuria. But the animals fed normally and moved
around in their cages freely.
Coronary PKC expression in wildtype and Ga11 knockout
animals under normoglycaemic conditions
To evaluate the influence of the g-protein Ga11 on the
coronary expression of the PKC isoforms a, bII, δ, ε and ζ,
which are known to take crucial part in the pathogenesis
of atherosclerosis, we compared wildtype control animals
(WT) and Ga11 knockout control animals (KO) (Figure 1).
Conventional PKC isoforms a (PKC a [densitometric
Units] WT: 185.02 ± 32.37; KO: 267.45 ± 73.54; p = 0.28)
(Figure 2A vs. Figure 3A) and bII (PKC bII; WT: 131.75 ±
41.62; KO: 222.18 ± 27.04; p = 0.098) (Figure 2E vs.
Figure 3E) were equally expressed in wildtype and knock-
out animals. The analysis of the nPKC isoforms ε and δ
both showed a significant attenuation of the expression in
coronary vessels in Ga11 knockout animals (PKC δ [densi-
tometric Units] WT: 719.84 ± 89.32; KO: 420.00 ± 58.38;
p = 0.018) (Figure 2G vs. Figure 3G) (PKC ε; WT: 671.65
± 81.3; KO: 327.15 ± 43.64; p = 0.0035) (Figure 2I vs.
Figure 3I). The atypical PKC isoform ζ (PKCζ; WT: 180.48
± 99.75; KO: 253.11 ± 38.45; p = 0.48) in turn was simi-
larly expressed in the coronary vessels of wildtype and
Ga11 knockout animals (Figure 2C vs. Figure 3C).
Coronary PKC expression after 8 weeks of hyperglycaemia
in wildtype and Ga11 knockout animals
After 8 weeks of diabetes the animals were sacrificed and
the coronary vessels were assessed for PKC isoform a, bII,
δ, ε and ζ expression. First we analyzed the expression of
the conventional PKC isoforms (cPKC) a and bII in wild-
type animals after 8 weeks of diabetes compared to age
matched controls (Figure 2). We detected a low level of
PKC a in diabetic animals (DM) and controls (C), which
was equivalent (PKC a [densitometric Units] C: 185.02 ±
32.37; DM: 203.23 ± 37.62; p = 0.72) (Figure 2A vs Figure
2B). PKC bII in the coronary vessels showed only a faint
expression with no alteration in the hyperglycaemic state
(PKC bII [densitometric Units] C: 131.75 ± 41.62; DM:
132.42 ± 20.41; p = 0.99) (Figure 2E vs Figure 2F). We
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(nPKC) ε and δ. 8 weeks of diabetes did not change the
high level of expression of PKC δ in coronary vessels of
wildtype animals (PKC δ [densitometric Units] C: 719.84 ±
89.32; DM: 640.82 ± 76.3; p = 0.52) (Figure 2G vs Figure
2H) in contrast to the likewise high level of expression of
PKC ε that was attenuated after 8 weeks of hyperglycaemia
(PKC ε [densitometric Units] C: 671.65 ± 81.3; DM: 421.99
± 35.86; p = 0.013) (Figure 2I vs Figure 2J). Next we stu-
died the expression of the atypical PKC isoform (aPKC) ζ.
This isoform did not show any significant alteration after
8 weeks of diabetes in wildtype animals (PKC ζ [densito-
metric Units] C: 180.48 ± 99.75; DM: 217.94 ± 39.17; p =
0.7) (Figure 2C vs Figure 2D).
In Ga11 knockout animals the same examinations were
performed comparing the expression of the PKC isoforms
a, bII, δ, ε and ζ in coronary vessels after 8 weeks of
hyperglycaemia to age matched controls (Figure 3). Again
the cPKC isoforms did not show any significant alterations
(PKC a [densitometric Units] C: 267.45 ± 73.54; DM:
202.62 ± 36.63; p = 0.43) (Figure 3A vs Figure 3B) (PKC
bII; C: 222.18 ± 27.04; DM: 180.28 ± 45.17; p = 0,43) (Fig-
ure 3E vs Figure 3F). PKC δ showed a lower level of
expression in the coronary vessels of Ga11 knockout
animals but again like in wildtype animals there was no
change of expression detectable after 8 weeks of hypergly-
caemia (PKC δ [densitometric Units] C: 420.00 ± 58.38;
DM: 412.68 ± 52.04; p = 0.93) (Figure 3G vs Figure 3H).
The second nPKC isoform analyzed in this study showed
a different pattern of expression in G11 knockout animals
than in wildtype animals after 8 weeks of diabetes. In Ga11
knockout animals the expression of PKC ε was not altered
in the coronary vessels after the diabetic period of time
(PKC ε [densitometric Units] C: 327.15 ± 43.64; DM:
464.1 ±76.79; p = 0.13) (Figure 3I vs Figure 3J). Again we
proceeded with examination of the aPKC isoform ζ. How-
ever PKC ζ demonstrated a significant decrease in the
expression in coronary vessels of Ga11 knockout mice
after 8 weeks of diabetes (PKC ζ [densitometric Units] C:
253.11 ± 38.45; DM: 132.16 ± 33.8; p = 0.042) (Figure 3C
vs Figure 3D) in contrast to wildtype animals.
Discussion
Diabetes mellitus is a crucial risk factor for developing
atherosclerosis. Common agreement exists on the role of
excessive neurohumoral stimu l a t i o ni nt h ep a t h o g e n e s i s
of atherosclerotic plaque formation in diabetes, involving
angiotensin II and endothelin-1. These hormones bind to
Table 1 Bodyweight and blood glucose levels of the animals at the end of the in vivo study
Wildtype Diabetes Wildtype Control Ga11 Knockout Diabetes Ga11 Knockout Control
n = 14 n = 10 n = 13 n = 13
Bodyweight (g) 20.5 ± 2.6 * 31.6 ± 2.5 25.2 ± 3.3 * 32.0 ± 5.1
Blood glucose (mg/dl) 491 ± 91 * 103 ± 12 432 ± 107 * 109 ± 9
Data are means ± plusorminus SEM.
* p < 0,05 vs. Control.
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Figure 1 Immunostaining of PKC isozymes in control Ga11 knockout animals compared to age matched control wildtype animals
(Ga11 knockout n = 6, wildtype n = 6). The nPKC isozymes δ and ε showed a diminished expression in Ga11 knockout animals. KO =
Knockout animals. * = p < 0.05 vs. Control. ** = p < 0.01 vs. Control.
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differential regulation of specific PKC isoforms. Large
clinical trials provided evidence of a lower incidence of
ischemic heart disease when patients were treated with
ACE inhibitors or AT1-receptor blockers compared to
other antihypertensive drugs independent of blood pres-
sure control [10,11]. These clinical observations are sup-
ported by animal models, in which the blockage of the
renin angiotensin system (RA S )s h o w e das i g n i f i c a n t l y
diminished progression of atherosclerosis [12,13]. The
goal of the present study therefore was to gain further
insight into the distribution of PKC isozymes in the
coronary vessels in a model of an early diabetes mellitus
and to define the role of the g-protein Ga11 on expres-
sion and localization of these kinases.
Early diabetes shows no specific regulation of the
conventional PKC isoforms a and bII
The conventional PKC isozymes a and bII have been
shown to take part in different steps of atherogenensis.
PKC a appears to be involved in O2
- mediated oxidation
of LDL serving as a chemotactant for monocytes and
may increase phospholipase A2 activation and monocyte
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Figure 2 Immunostaining of PKC isozymes in Wildtype animals after 8 weeks of experimental diabetes compared to age matched
control animals (control n = 6, diabetes n = 6). PKC ε showed a diminished expression upon the induction of diabetes in wildtype animals.
DM = Diabetes mellitus. * = p < 0.05 vs. control. bar = 60 μm.
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Page 5 of 8expression, resulting in endothelial adhesion. PKC a has
further been shown to stimulate VSMC for translocation
and vasoconstriction [15] and to increase MMP-2
expression leading to plaque instability [16]. PKC bII
appears to be involved in the expression of vascular cell
adhesion molecule (VCAM) and inter-cellular adhesion
molecule (ICAM) leading to monocyte recruitment and
adhesion [17]. In our studies the levels of expression
and location of conventional PKC isozymes a and bII
were unchanged. Hence, in our present study there
appears to be no specific regulation of these PKC iso-
forms in the coronary vessels in early diabetes.
The atypical PKC isoform ζ is reduced in early diabetes
after deletion of Ga11
Sorescu and coworkers showed that PKC ζ can activate
the NADPH oxidase supporting the pro-oxidant environ-
ment of the atherosclerotic lesion by increasing reactive
oxygen species production, thus leading to apoptosis and
plaque instability [1]. In addition, the secretion of MMPs
can be increased up to 13-fold through PKC ζ activity
[18] promoting the degradation of extracellular matrix
proteins. This pathomechanism has been linked to an
increased risk of plaque rupture. In our Ga11 knockout
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Figure 3 Immunostaining of PKC isozymes in Ga11 knockout animals after 8 weeks of experimental diabetes compared to age
matched control animals (control n = 6, diabetes n = 6). PKC ζ showed a decreased expression upon induction of diabetes in Ga11
knockout animals. DM = Diabetes mellitus. * = p < 0.05 vs. control. bar = 60 μm.
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the current knowledge about the pathogenic role of PKC
ζ in atherosclerosis this reduction in protein densities
may thus reflect a protective mechanism in response to
the deletion of the g-protein Ga11.
Expression of the new PKC isoforms δ and ε is under
control of Ga11
Compared to wildtype controls, expression of the nPKC
isozymes δ and ε, which are activated independently of
calcium but in dependence of DAG, were diminished in
Ga11 knockout animals. This indicates strongly that
expression of these isozymes is at least in part regulated
b yaG a11-dependent pathway. Ma and coworkers pro-
vided evidence that PKC δ mediates the accumulation of
oxidative LDL (oxLDL) in macrophages [19] leading to
the formation of foam cells as one of the major mechan-
isms in the genesis of atherosclerotic lesions. Further-
more, there is evidence in support of a proapoptotic
function of PKC δ in different cell types including
VSMC [20]. In the pathogenesis of atherosclerosis,
apoptosis of VSMCs is a central process leading to a
marked thinning of the fibrous cap, the loss of collagen
and matrix, accumulation of cell debris and intimal
inflammation [21]. Following this line of evidence, the
lower level of expression of the nPKC δ that we
observed in nondiabetic Ga11 knockout mice compared
to wildtype controls would target several processes that
are crucial for atherosclerotic plaque formation. Hence,
the Ga11 -dependent reduction in PKC δ expression
could provide a protective mechanism in atherosclerotic
heart disease. This view is supported by the persistent
low expression of this isozyme in Ga11 knockout mice
even after induction of diabetes, one of the primary risk
factors for atherosclerosis.
T h er o l eo fP K Cε in coronary vessels is not yet fully
understood but evidence accumulates for an antiproli-
ferative and antiapoptotic effect on VSMCs. Among
others, this was nicely demonstrated by Sasaguri and
coworkers showing that PKC ε suppresses proliferation
of VSMCs by inhibition of the cell cycle at the late G1
phase [22]. In addition activation of PKC ε has been
shown to protect against apoptosis through inhibition of
the tumor necrosis factor TNFa and activation of tran-
scriptional factor NF-B via phosphorylation of IB
kinase [23-25]. Recently, Min and coworkers provided
evidence for activation of the PKC/NF-Bp a t h w a yi n
neonatal rat cardiomyocytes exposed to high glucose
further supporting the importance of this pathway in
the diabetic heart [26].
It seems that PKC ε is further linked to raf-1 kinase
activation and the mitogen-activated protein kinase path-
way and it has been shown that this isoform mediates the
effect of angiotensin II in the proximal tubule of the kid-
ney [27]. In our present study protein levels of PKC ε
were reduced in coronary vessels from wildtype mice 8
weeks after induction of diabetes. Similarly, the reduced
expression of this isoform following hyperglycemia has
previously been described in myocardial tissue [28,29]
and a resulting susceptibility for postischemic damage
has been postulated. If expression of the nPKCs δ and ε
were under control of a Ga11-dependent signaling path-
way we hypothesized that densities of these proteins
would not be influenced by strong stimuli like hypergly-
cemia. The present results support this hypothesis, how-
ever, functional implications that would result from this
permanent downregulation and possible mechanisms of
compensation by other pathways are not yet fully under-
stood. It is also to be considered that individual PKC
isoforms may mutually regulate their activity as part of a
concerted process involving a network of signalling cas-
cades [30]. Further studies will be needed to address
these functional aspects.
Conclusion
In conclusion, the present study shows that expression
of the nPKCs δ and ε in coronary vessels is under con-
trol of the g-protein Ga11. The reduced expression of
PKC ζ that we observed in coronary arteries from Ga11-
knockout mice compared to wildtype controls upon
induction of diabetes could reduce apoptosis and pro-
mote plaque stability. These findings suggest a mechan-
ism that may in part underlie the therapeutic benefit of
RAS inhibition on cardiovascular endpoints in diabetic
patients.
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